Too much iron: A masked foe for leukemias

Eolia Brissot (1) , Delphine G Bernard (2) , Olivier Loréal (3) , Pierre Brissot (3) , Marie-Bérengère Troadec (2)

1 CRSA - Centre de Recherche Saint-Antoine
2 GGB - Génétique, génomique fonctionnelle et biotechnologies (UMR 1078)
3 NuMeCan - Nutrition, Métabolismes et Cancer

The role of iron in non-erythroid hematopoietic lineages and its implication in hemato-oncogenesis are still debated. Iron exerts an important role on hematopoietic stem cell transformation and on mature white blood cell differentiation. Iron acts experimentally as an oncogenic cofactor but its exact role in the transformation of the myelodysplastic syndrome into leukemia continues to be discussed. Body iron overload frequently develops mainly as the result of multiple erythrocyte transfusions in patients with leukemia or myelodysplastic syndrome, and, in the latter, as a result of increased ineffective erythropoiesis. Iron overload, especially through the deleterious effects of reactive oxygen species, leads to organ damage that likely impacts the global outcome of patients, especially after hematopoietic stem cell transplantation (HSCT). In these pathological settings (before and after HSCT), oral iron chelation should be considered whenever body iron overload has been firmly established, ideally by magnetic resonance imaging.

Keywords: Hematopoietic stem cell transplantation; Iron; Leukemia; Myelodysplastic syndrome; Oral chelation; Phlebotomy

Domains: Life Sciences [q-bio]; Human health and pathology; Hematology; Life Sciences [q-bio]; Cancer

Eolia Brissot, Delphine G Bernard, Olivier Loréal, Pierre Brissot, Marie-Bérengère Troadec. Too much iron: A masked foe for leukemias. Blood Reviews, 2020, 39, pp.100617. ⟨10.1016/j.blre.2019.100617⟩. ⟨hal-02472239⟩